Funds and ETFs Hangzhou Tigermed Consulting Co., Ltd
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
53.25 CNY | -2.65% | -6.37% | -3.13% |
04-25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
04-25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
ETFs positioned on Hangzhou Tigermed Consulting Co., Ltd
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +4.71% | - | |
0.00% | 7 M€ | +0.11% | - | |
0.00% | 8 M€ | +0.16% | - | |
0.00% | 15 M€ | +16.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.13% | 5.96B | |
+51.02% | 56.69B | |
-3.57% | 41B | |
+38.14% | 38.11B | |
-11.22% | 26.89B | |
+14.04% | 25.59B | |
-22.07% | 18.59B | |
-0.08% | 12.39B | |
+26.58% | 11.99B | |
+22.79% | 11.88B |
- Stock Market
- Equities
- 300347 Stock
- Funds and ETFs Hangzhou Tigermed Consulting Co., Ltd